Sitryx Therapeutics Ltd. has identified itaconate compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of psoriasis, asthma, systemic lupus erythematosus, chronic obstructive pulmonary disease (COPD) and multiple sclerosis.